(MENAFN- Baystreet.ca)
Patient Dosing Resumes in Alzheimer's Clinical Trial
Treatments for Alzheimer's continue to be lacking in the clinical community. This drug repurposing is hoping to be an effective treatment for mild to moderate AD.
After a delay due to the global pandemic, leading drug delivery company IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) has resumed patient dosing in the ongoing Phase 2a ('BUENA') clinical trial. Under the previously amended protocol, higher doses of Montelukast VersaFilm are used in patients with mild to moderate Alzheimer's Disease, per the company's press release.
IntelGenx management believes that the treatment has the potential to modify treatment of the disease.
Shares were trading up at $0.44 in afternoon trade.
MENAFN20012022000212011056ID1103571083
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.